MedTrace Logo

Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy

NCT05418465 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-06-14

No results posted yet for this study

Summary

This is a prospective, open, multicenter clinical trial.The objective of this study is to evaluate the efficacy and safety of Huangqi Guizhi Wuwu Decoction in patients with CKD stage 2-4 diabetic nephropathy.

Conditions

  • Diabetic Nephropathies

Interventions

DRUG

Huangqi Guizhi Wuwu decoction

Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.

DRUG

Dapagliflozin

Dapagliflozin, 10mg at a time, once a day. Oral administration.

Sponsors & Collaborators

  • The First Affiliated Hospital of Dalian Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-26
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05418465 on ClinicalTrials.gov